chlorambucil news

All news on chlorambucil (also known as Leukeran and 4-[4-(bis(2-chloroethyl)amino)phenyl]butanoic acid): plants, production capacities, investments and involved companies.

14 July 2026

Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy

FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.
20 April 2026

FDA Accepts Genentech sBLA for Gazyva in SLE

FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.

Who will be producing chlorambucil in the future?

Find out with chemXplore Alpha

Learn more